Skip to content
LATEST
Health

South Korean Obesity Drug Market Approaches $1.44 Billion Amid Safety Concerns

South Korea’s obesity drug market is nearing $1.44 billion in annual sales, but regulators have issued warnings regarding potential vision-loss risks amid…

South Korean Obesity Drug Market Approaches $1.44 Billion Amid Safety Concerns

The South Korean market for GLP-1 receptor agonist obesity treatments is projected to reach approximately $1.44 billion in annual revenue by the end of the year. Data indicates that the market grew from $81 million in the first quarter of last year to $403 million in the second quarter of this year, driven largely by the introduction of high-efficacy injectable medications. Currently, one dominant product accounts for roughly 75% of the total market share, with other competitors and domestic manufacturers expected to increase their presence in the coming months.

Institutional expansion continues to track with this market growth. A major domestic contract development and manufacturing organization recently completed a $1.95 billion capital increase to acquire international peptide production capabilities, signaling long-term investment in the global obesity drug supply chain. Despite this commercial momentum, the rapid expansion has outpaced clinical oversight and patient education protocols.

Regulatory authorities in both the United States and Regulatory authorities in both the United States and South Korea have issued safety warnings regarding a rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can lead to permanent vision loss. Health officials have confirmed at least one suspected case of NAION in South Korea, prompting the distribution of safety advisories to medical practitioners.

Reports suggest that the widespread use of these drugs for cosmetic weight loss has led to inconsistent clinical practices. Patients have reported receiving prescriptions without adequate counseling on potential side effects or contraindications, often relying on social media for health information rather than medical professionals. Pharmaceutical manufacturers have responded by stating they are monitoring ocular adverse event data and will comply with regulatory guidance to ensure that both healthcare providers and patients are appropriately informed. The discrepancy between rapid market adoption and the quality of patient risk communication remains a significant governance challenge for healthcare providers and regulators.

More stories

Latest news